Jevtana

Cabazitaxel, the active ingredient in Jevtana, is a taxane class antineoplastic presented as a powder for injection for intravenous infusion. It is indicated for the treatment of metastatic castration‑resistant prostate cancer in adult patients who have progressed after docetaxel therapy.

GNH USA supplies Jevtana as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, providing EU‑sourced product with full regulatory documentation.

Jevtana (cabazitaxel) is used within the taxane chemotherapy pathway for advanced prostate cancer.

- Metastatic castration‑resistant prostate cancer: improves overall survival in patients previously treated with docetaxel. - Advanced prostate cancer after docetaxel failure: offers an alternative taxane option to control disease progression. - Prostate adenocarcinoma with progression: reduces tumor burden when combined with standard corticosteroid support.

Cabazitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count leading to infection risk. - Fatigue: persistent tiredness affecting daily activities. - Anemia: reduced red blood cell levels causing weakness. - Nausea: upset stomach often accompanied by vomiting. - Diarrhea: loose stools that may require supportive care. - Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent treatment. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Peripheral neuropathy: nerve damage causing tingling or pain. - Life‑threatening infections: sepsis or pneumonia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Cardiac events: arrhythmias or myocardial ischemia.

Prior to initiating cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications.

- Monitor blood counts: perform regular CBC to detect neutropenia and anemia. - Assess hepatic function: adjust dosing in patients with liver impairment. - Evaluate for hypersensitivity: observe for infusion‑related reactions during administration. - Use caution in elderly: increased risk of myelosuppression and infection. - Avoid in active severe infection: postpone treatment until infection resolves. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Concurrent myelosuppressive agents: heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): may modestly raise plasma levels. - Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk. - Neurotoxic drugs (e.g., vincristine): observe for additive peripheral neuropathy.